Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

Novo’s CagriSema shot was shown to be less effective than rival Lilly’s tirzepatide ...

The Danish drugmaker’s latest trial setback intensifies its high-stakes rivalry with Eli Lilly in the booming obesity market.

Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a ...

The drugmaker unveiled a new Zepbound delivery system as its main rival absorbed fresh clinical and stock-market blows. It’s ...

The list price of Wegovy will be cut in half on January 1, 2027, plummeting from around $1,350 to $675 a month. The cost of ...

The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a statement Tuesday, Feb. 24 ...

Starting in 2027, the Danish pharma firm will sell its weight-loss and diabetes drugs for $675 per month.

Novo Nordisk announced up to 50% price cuts for Ozempic and Wegovy diabetes and weight-loss drugs starting January 2027, ...

Novo Nordisk will slash list prices of the blockbuster diabetes and weight-loss medications Ozempic, Rybelsus, and Wegovy.

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, 2027, ...

Novo Nordisk announced plans to drastically reduce the list price of its versions, Wegovy, Ozempic and Rybelsus.